FDA approves first natalizumab biosimilar for MS treatment
Medical News Today,
Share on PinterestTyruko, a biosimilar of Tysabri, has now been approved by the FDA for the treatment of MS.
Share on PinterestTyruko, a biosimilar of Tysabri, has now been approved by the FDA for the treatment of MS.
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitti…
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitti…
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitti…